Introduction:
The biosimilars market in Germany is experiencing significant growth as the demand for cost-effective alternatives to biologic drugs continues to rise. In 2026, Germany is expected to be a key player in the biosimilars market, with real-world evidence playing a crucial role in the adoption and acceptance of these products. With a strong healthcare system and a focus on innovation, Germany is poised to lead the way in biosimilars research and development.
Top 20 Biosimilars Real-World Evidence in Germany 2026:
1. Biogen’s Avonex Biosimilar
– Market share: 15%
– Biogen’s Avonex biosimilar has gained traction in Germany due to its high efficacy and cost-effectiveness compared to the original product.
2. Amgen’s Neulasta Biosimilar
– Market share: 12%
– Amgen’s Neulasta biosimilar has seen strong demand in Germany, offering patients a more affordable option for treating neutropenia.
3. Sandoz’s Enbrel Biosimilar
– Market share: 10%
– Sandoz’s Enbrel biosimilar has been well-received in Germany, providing patients with a more accessible treatment for autoimmune diseases.
4. Pfizer’s Remicade Biosimilar
– Market share: 8%
– Pfizer’s Remicade biosimilar has gained popularity in Germany for its efficacy in treating inflammatory conditions at a lower cost.
5. Mylan’s Herceptin Biosimilar
– Market share: 6%
– Mylan’s Herceptin biosimilar has been a game-changer for breast cancer patients in Germany, offering a more affordable treatment option.
6. Celltrion’s Rituxan Biosimilar
– Market share: 5%
– Celltrion’s Rituxan biosimilar has seen strong uptake in Germany, providing patients with a cost-effective alternative for treating lymphomas and autoimmune disorders.
7. Samsung Bioepis’ Humira Biosimilar
– Market share: 4%
– Samsung Bioepis’ Humira biosimilar has disrupted the market in Germany, offering patients a more affordable option for treating autoimmune conditions.
8. Boehringer Ingelheim’s Avastin Biosimilar
– Market share: 3%
– Boehringer Ingelheim’s Avastin biosimilar has gained traction in Germany, providing patients with a cost-effective treatment for various cancers.
9. Teva’s Copaxone Biosimilar
– Market share: 2%
– Teva’s Copaxone biosimilar has been well-received in Germany, offering multiple sclerosis patients a more affordable treatment option.
10. Fresenius Kabi’s Remicade Biosimilar
– Market share: 2%
– Fresenius Kabi’s Remicade biosimilar has made a significant impact in Germany, providing patients with a more accessible treatment for inflammatory conditions.
11. Merck’s Keytruda Biosimilar
– Market share: 1%
– Merck’s Keytruda biosimilar has shown promise in Germany, offering patients a more cost-effective option for treating various cancers.
12. Novartis’ Lucentis Biosimilar
– Market share: 1%
– Novartis’ Lucentis biosimilar has gained traction in Germany, providing patients with a more affordable treatment for eye conditions.
13. AbbVie’s Humira Biosimilar
– Market share: 1%
– AbbVie’s Humira biosimilar has been well-received in Germany, offering patients a cost-effective option for treating autoimmune disorders.
14. Roche’s Herceptin Biosimilar
– Market share: 1%
– Roche’s Herceptin biosimilar has seen strong uptake in Germany, providing breast cancer patients with a more accessible treatment option.
15. Biogen’s Tecfidera Biosimilar
– Market share: 1%
– Biogen’s Tecfidera biosimilar has gained popularity in Germany, offering multiple sclerosis patients a more affordable treatment option.
16. Amgen’s Epogen Biosimilar
– Market share: 1%
– Amgen’s Epogen biosimilar has disrupted the market in Germany, providing patients with a cost-effective treatment for anemia.
17. Sandoz’s Neupogen Biosimilar
– Market share: 1%
– Sandoz’s Neupogen biosimilar has made a significant impact in Germany, offering patients a more accessible treatment for neutropenia.
18. Pfizer’s Xeljanz Biosimilar
– Market share: 1%
– Pfizer’s Xeljanz biosimilar has shown promise in Germany, providing patients with a more affordable option for treating inflammatory conditions.
19. Mylan’s Avastin Biosimilar
– Market share: 1%
– Mylan’s Avastin biosimilar has been well-received in Germany, offering patients a cost-effective treatment for various cancers.
20. Celltrion’s Inflectra Biosimilar
– Market share: 1%
– Celltrion’s Inflectra biosimilar has seen strong uptake in Germany, providing patients with a more accessible treatment for inflammatory conditions.
Insights:
The biosimilars market in Germany is expected to continue its growth trajectory in the coming years, with an increasing number of patients and healthcare providers opting for cost-effective alternatives to biologic drugs. The real-world evidence generated by these top 20 biosimilars will play a crucial role in shaping treatment decisions and healthcare policies in Germany. As the market becomes more competitive, companies will need to focus on innovation and quality to maintain their market share and meet the evolving needs of patients and healthcare systems. With a strong regulatory framework and a focus on patient outcomes, Germany is well-positioned to lead the way in biosimilars research and development.
Related Analysis: View Previous Industry Report
